Key Takeaway: Molecular Partners is making significant progress in its Phase 2 TACTIC trial for MP0317, targeting cholangiocarcinoma. The study is currently active with nine sites recruiting patients. An update on the trial data is expected in 2027, with completion projected for 2028. A trial-in-progress poster will be presented at ESMO 2026.
Price reaction · baseline $3.91 (2026-07-15 close) · hit pre-market · clean, no other MOLN news in the window
day 0 close · peak
+4.9%
Market Sentiment Analysis
POSITIVE FACTORS
Phase 2 study is progressing well with active recruitment.
Nine sites are currently involved in patient treatment.
Data update anticipated in 2027 indicates ongoing progress.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+104%
120-day peak, hindsight
Typical move
8.3%
average across 2 past catalysts
Lead asset
ensovibep
Phase 2 · Covid19
Full Press Release Details
Randomized Phase 2 study in front-line setting progressing well, with nine sites actively recruiting and patient treatment ongoing Data update expected in 2027, with trial completion in 2028 Trial-in-progress poster to be presented at ESMO 2026 in October ZURICH-SCHLIEREN, Switzerland and CONCORD,
Frequently Asked Questions
What is the TACTIC trial?
The TACTIC trial is a Phase 2 study evaluating MP0317 for cholangiocarcinoma.
How many sites are involved in the trial?
There are nine sites actively recruiting patients for the trial.
When is the data update expected?
A data update from the trial is expected in 2027.
When will the trial be completed?
The trial is projected to be completed in 2028.
Where will the trial poster be presented?
The trial-in-progress poster will be presented at ESMO 2026.